Moderna PP&E per Employee
PP&E per Employee of Moderna (MRNA) as of Sep 10, 2026.
Get this data via API
Financial Data API
PP&E per Employee
0.00USD
Last updated:
PP&E per Employee of Moderna is 2026 0.00 USD. PP&E per Employee of Moderna was 2025 0.00 USD. It decreases by % lower compared to the previous year.
The Moderna PP&E per Employee history
3 Years
10 Years
25 Years
Max
PP&E per Employee
Date
PP&E per Employee
Jan 1, 2016
97,839.76 USD
Jan 1, 2017
167,507.23 USD
Jan 1, 2018
255,393.98 USD
Jan 1, 2019
346,878.31 USD
Jan 1, 2020
466,373.49 USD
Jan 1, 2021
1.67 M USD
Jan 1, 2022
2.58 M USD
| YEAR | PP&E per Employee | YoY |
|---|---|---|
| 2.58 MUSD | +54.66% | |
| 1.67 MUSD | +257.28% | |
| 466,373.49USD | +34.45% | |
| 346,878.31USD | +35.82% | |
| 255,393.98USD | +52.47% | |
| 167,507.23USD | +71.21% | |
| 97,839.76USD | — |
Access this data via the Eulerpool API
Moderna Stock analysis
What does Moderna do? Moderna Inc is a biotechnology company from the USA that specializes in the development of therapies and vaccines based on mRNA technology. The company was founded in 2010 by a group of researchers led by Noubar Afeyan and is headquartered in Cambridge, Massachusetts. Moderna is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Moderna stock
On Eulerpool you can find the complete historical development of PP&E per Employee Moderna since 2006 – with annual values, charts, and detailed analysis.
PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.
PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Moderna historically and in real time.
Access this data via the Eulerpool API
Workforce — Moderna
All Key Metrics — Moderna
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth